Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Immuno-Oncology Tumor Model Development Services
Solutions
Online Inquiry

Immuno-Oncology Tumor Model Development Services

With extensive experience in immuno-oncology research and advanced technologies, Alfa Cytology is committed to providing our clients with one-stop immuno-oncology tumor model development services. Our goal is to provide reliable, reproducible and translatable models that accurately reflect human disease, to accelerate the process of translating from the lab to therapy.

Overview of Immuno-Oncology Tumor Models

Immuno-oncology models are preclinical models used to study the interaction between the immune system and cancer cells. These models contain various elements of the tumor microenvironment, including immune cells, stromal cells, and extracellular matrix components, and are designed to mimic the complex interactions between the immune system and cancer cells in humans.

Fig. 1 Mouse models in immune-oncology.Fig.1 Mouse models in oncoimmunology. (Zitvogel, L., et al., 2016)

There are several types of immuno-oncology models, including mouse models, cell line models and patient xenograft models. They are critical for evaluating new immunotherapies, including checkpoint inhibitors, CAR-T cell therapies and cancer vaccines, and these models help decipher the immune responses elicited by these treatments, allowing researchers to study human-specific immune responses and the effectiveness of immunotherapeutic agents in a controlled, reproducible manner.

Our Services

Alfa Cytology is committed to advancing the development of innovative cancer therapies through specialized preclinical services. We provide a one-stop shop for the development of immuno-oncology tumor models, to support research institutions and companies in the discovery and improvement of novel cancer therapies.

Immuno-Oncology Tumor Models Available

Alfa Cytology's animal model platform offers a wide range of validated immuno-oncology tumor models to choose from, each with unique benefits to ensure comprehensive support for a variety of research needs.

Syngeneic Tumor Model

Used to study tumor-immune interactions in fully immunocompetent hosts, to effectively assess the efficacy of immunotherapies, and to study mechanisms of immune escape and resistance.

Humanized Mouse Model

Used to study human-specific immune responses, allowing for more accurate prediction of the efficacy and safety of human-targeted immunotherapeutic agents and increasing the translational value of preclinical studies.

Immuno-Oncology Pharmacodynamic Model

Used to study the pharmacodynamics and pharmacokinetics of immunotherapeutic agents, providing critical data for optimization of dosing regimens, evaluation of combination therapies, and identification of predictive biomarkers.

Service Process for Immuno-Oncology Tumor Model Development

Workflow of Immuno-Oncology Tumor Model Development

Consultation and Project Design

Initial discussions to understand the specific needs and objectives of the research project.
Custom-tailored project plans that align with client goals and scientific requirements.

Model Selection and Development

Selection of the appropriate tumor model (syngeneic, humanized, or PDX) based on the project’s objectives.
Development of models that accurately reflect the human disease context for robust preclinical testing.

In Vivo Studies

Conducting in vivo experiments to evaluate the efficacy and mechanism of action of immunotherapeutic agents.
Generation of high-quality, reproducible data that supports clinical translation.

Data Analysis and Reporting

Comprehensive analysis of experimental data using advanced bioinformatics tools.
Detailed reports that provide actionable insights and support regulatory submissions.

Alfa Cytology has extensive experience, strong expertise and cutting-edge technology in immuno-oncology model development to provide reliable models for preclinical studies of cancer therapies. Our comprehensive services ensure that clients receive accurate, actionable data to advance their fast-track development programs. For more information and to discuss project requirements, please contact us.

Reference

  1. Zitvogel, L., et al.; (2016). Mouse models in oncoimmunology. Nature Reviews Cancer, 16(12), 759-773.

For research use only.